Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII

BAY 81‐8973 is a full‐length recombinant factor VIII (FVIII) with the same primary amino acid sequence as sucrose‐formulated recombinant FVIII (rFVIII‐FS) but is produced with advanced manufacturing technologies.

[1]  J. Oldenburg,et al.  Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  C. Kempton,et al.  Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) , 2013, Journal of thrombosis and haemostasis : JTH.

[3]  C. Kempton,et al.  Randomized, Controlled, Parallel-Group Trial of Routine Prophylaxis Versus On-Demand Treatment With rFVIII-FS in Adults With Severe Hemophilia A (SPINART). , 2013 .

[4]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[5]  M. Morfini,et al.  Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover study , 2010, Journal of thrombosis and haemostasis : JTH.

[6]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[7]  L. Havekes,et al.  The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor , 2005, Journal of thrombosis and haemostasis : JTH.

[8]  C. Rothschild,et al.  Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A , 2005, Thrombosis and Haemostasis.

[9]  P. Mannucci,et al.  Human recombinant DNA‐derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation , 2004, Journal of thrombosis and haemostasis : JTH.

[10]  H. Brackmann,et al.  Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy , 2000, Thrombosis and Haemostasis.

[11]  H. Brackmann,et al.  Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. , 2000, Thrombosis and haemostasis.

[12]  S. Arkin,et al.  Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. , 1993, The New England journal of medicine.